Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of mesenchymal stem cell therapy for the treatment of Aging Frailty in Japanese patients: A randomized, double-blind, placebo-controlled study

Next Previous
Search
Trial Profile

Phase II study of mesenchymal stem cell therapy for the treatment of Aging Frailty in Japanese patients: A randomized, double-blind, placebo-controlled study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laromestrocel (Primary)
  • Indications Asthenia
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 27 Feb 2024 According to a Longeveron media release, in line with the companys 2024 strategic direction to focus its resources on HLHS and AD and to manage its cash spend, the company has discontinued this clinical trial in Japan to evaluate Lomecel-B™ for Aging-related Frailty in order to focus on its strategic priority in HLHS.
    • 27 Feb 2024 Status changed from recruiting to discontinued, according to a Longeveron media release.
    • 11 Sep 2023 According to a Longeveron media release, primary endpoint is safety with an overarching goal of providing support for an eventual limited approval under the Japan's Act on the Safety of Regenerative Medicine, or ASRM, which recognizes the tremendous potential, therapeutic potential of cell therapies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top